Login to Your Account

Focus on ERTs as Synageva Inks Trimeris Reverse Merger

By Jennifer Boggs

Tuesday, June 14, 2011
Only a few months after pulling in $25 million in equity funding, privately held Synageva BioPharma Corp. is gaining access to the public markets, as well as a nice chunk of cash, in a planned stock-for-stock merger with Trimeris Inc.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription